Can’t Access Weight Loss Injections on the NHS ? Here’s How Regulated Online Pharmacies Are Helping

Last updated: 18 September 2026

NHS access to weight-management medicines is expanding in phases, but it is not available to everyone straight away. This guide explains the current position for tirzepatide (Mounjaro) in England, how eligibility is assessed, and what to do if you are not eligible for NHS treatment.

Can you get Mounjaro for weight management on the NHS?

Tirzepatide (Mounjaro) is recommended by NICE for some adults living with obesity, alongside a reduced-calorie diet and increased physical activity. Access is being introduced in stages so that NHS services can provide the necessary clinical and behavioural support safely.

Eligibility is not determined by a single national waiting list. Your local integrated care board, GP practice and specialist weight-management service determine whether an assessment is available and whether treatment is clinically suitable for you.

Who may be eligible now?

NICE and NHS England set out a phased approach for primary-care access in England. The prioritised groups are based on BMI and the number of weight-related health conditions a person has. The relevant conditions include high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.

The staged thresholds include lower BMI cut-offs for some ethnic backgrounds. From around June 2026, the next phase includes people with four or more listed conditions and a BMI of 35 to 39.9 kg/m². The earlier highest-priority group includes people with four or more listed conditions and a BMI of 40 kg/m² or above. Specialist weight-management services may assess people under the broader NICE recommendation where treatment is appropriate.

These are assessment criteria, not a guarantee of a prescription. A clinician will consider your health, other medicines, risks, preferences and ability to take part in the required support programme.

Why does access vary?

NHS England is phasing implementation over three years while services build capacity, train clinicians and provide wraparound care. That care includes medical reviews and behavioural support around diet and physical activity. Local availability can therefore differ, even where a person appears to meet the national criteria.

What should you do if you want an NHS assessment?

• Speak to your GP practice or local specialist weight-management service.
• Ask whether your local integrated care board is accepting referrals or assessments for tirzepatide.
• Discuss your BMI, relevant health conditions and current medicines with a clinician.
• Do not buy prescription medicines through social media or unverified sellers if access is not immediately available.

What if you are not eligible or cannot access a local service?

Not being eligible for NHS treatment now does not mean treatment is appropriate privately. Any private prescription should follow a proper clinical assessment by a qualified prescriber. Check that any online pharmacy is registered with the General Pharmaceutical Council and that it provides a clear route for clinical advice and follow-up.

For more on verifying an online provider, see our guide to buying Mounjaro safely from a GPhC-registered pharmacy.

Important safety information

Tirzepatide is not suitable for everyone. Do not start, stop or change treatment without clinical advice. If you are pregnant, planning pregnancy, breastfeeding, taking the contraceptive pill, or have a medical condition or other medicines to consider, speak to a healthcare professional before treatment.

This article is for general information and is not medical advice. Prescription treatment is supplied only after a clinical assessment.

Sources

• NICE TA1026: Tirzepatide for managing overweight and obesity.
• NHS England: Weight management injections.
• NHS England: Interim commissioning guidance.

Last updated: 17 September 2026.